Indian pharmaceutical companies, after decades of navigating challenges in the US market, have become larger and more stable. While US FDA inspections continue, their frequency has decreased. Analysts suggest it may be an opportune time to reconsider pharmaceutical stocks, recommending a diversified portfolio approach rather than concentrating on individual companies.